221 related articles for article (PubMed ID: 25602245)
1. Advances in the treatment of tuberous sclerosis complex.
Leclezio L; de Vries PJ
Curr Opin Psychiatry; 2015 Mar; 28(2):113-20. PubMed ID: 25602245
[TBL] [Abstract][Full Text] [Related]
2. [Neuropsychiatric manifestations in Tuberous Sclerosis Complex (TSC): diagnostic guidelines, TAND concept and therapy with mTOR inhibitors].
Waltereit R; Feucht M; de Vries MC; Huemer J; Roessner V; de Vries PJ
Z Kinder Jugendpsychiatr Psychother; 2019 Mar; 47(2):139-153. PubMed ID: 30080117
[TBL] [Abstract][Full Text] [Related]
3. Neurological and neuropsychiatric aspects of tuberous sclerosis complex.
Curatolo P; Moavero R; de Vries PJ
Lancet Neurol; 2015 Jul; 14(7):733-45. PubMed ID: 26067126
[TBL] [Abstract][Full Text] [Related]
4. The TAND checklist: a useful screening tool in children with tuberous sclerosis and neurofibromatosis type 1.
Cervi F; Saletti V; Turner K; Peron A; Bulgheroni S; Taddei M; La Briola F; Canevini MP; Vignoli A
Orphanet J Rare Dis; 2020 Sep; 15(1):237. PubMed ID: 32894194
[TBL] [Abstract][Full Text] [Related]
5. Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist.
de Vries PJ; Whittemore VH; Leclezio L; Byars AW; Dunn D; Ess KC; Hook D; King BH; Sahin M; Jansen A
Pediatr Neurol; 2015 Jan; 52(1):25-35. PubMed ID: 25532776
[TBL] [Abstract][Full Text] [Related]
6. Pilot validation of the tuberous sclerosis-associated neuropsychiatric disorders (TAND) checklist.
Leclezio L; Jansen A; Whittemore VH; de Vries PJ
Pediatr Neurol; 2015 Jan; 52(1):16-24. PubMed ID: 25499093
[TBL] [Abstract][Full Text] [Related]
7. Tuberous sclerosis: a review of the past, present, and future.
Uysal SP; Şahin M
Turk J Med Sci; 2020 Nov; 50(SI-2):1665-1676. PubMed ID: 32222129
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus relieves seizures and neuropsychiatric symptoms via changes of microglial polarity in tuberous sclerosis complex model mice.
Koike-Kumagai M; Fujimoto M; Wataya-Kaneda M
Neuropharmacology; 2022 Nov; 218():109203. PubMed ID: 35931213
[TBL] [Abstract][Full Text] [Related]
9. From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches.
Ehninger D
Neuropharmacology; 2013 May; 68():97-105. PubMed ID: 22626986
[TBL] [Abstract][Full Text] [Related]
10. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.
Franz DN; Capal JK
Orphanet J Rare Dis; 2017 Mar; 12(1):51. PubMed ID: 28288694
[TBL] [Abstract][Full Text] [Related]
11. Involvement of mental health professionals in the treatment of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND): results of a multinational European electronic survey.
Waltereit R; Beaure d'Augères G; Jancic J; Kingswood JC; Koleva M; Marques R; Villanueva V; Auvin S
Orphanet J Rare Dis; 2021 May; 16(1):216. PubMed ID: 33980296
[TBL] [Abstract][Full Text] [Related]
12. Tuberous Sclerosis Complex Associated Neuropsychiatric Disorders and Parental Stress: Findings from a National, Prospective TSC Surveillance Study.
Ebrahimi-Fakhari D; Hussong J; Flotats-Bastardas M; Ebrahimi-Fakhari D; Zemlin M; von Gontard A; Meyer S
Neuropediatrics; 2019 Oct; 50(5):294-299. PubMed ID: 31266065
[TBL] [Abstract][Full Text] [Related]
13. Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review.
Sadowski K; Kotulska K; Schwartz RA; Jóźwiak S
J Eur Acad Dermatol Venereol; 2016 Apr; 30(4):586-94. PubMed ID: 26403211
[TBL] [Abstract][Full Text] [Related]
14. Possible prevention of tuberous sclerosis complex lesions.
Kotulska K; Borkowska J; Jozwiak S
Pediatrics; 2013 Jul; 132(1):e239-42. PubMed ID: 23733802
[TBL] [Abstract][Full Text] [Related]
15. International consensus recommendations for the identification and treatment of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND).
de Vries PJ; Heunis TM; Vanclooster S; Chambers N; Bissell S; Byars AW; Flinn J; Gipson TT; van Eeghen AM; Waltereit R; Capal JK; Cukier S; Davis PE; Smith C; Kingswood JC; Schoeters E; Srivastava S; Takei M; Gardner-Lubbe S; Kumm AJ; Krueger DA; Sahin M; De Waele L; Jansen AC
J Neurodev Disord; 2023 Sep; 15(1):32. PubMed ID: 37710171
[TBL] [Abstract][Full Text] [Related]
16. Mammalian Target of Rapamycin Inhibitors and Life-Threatening Conditions in Tuberous Sclerosis Complex.
Moavero R; Romagnoli G; Graziola F; Curatolo P
Semin Pediatr Neurol; 2015 Dec; 22(4):282-94. PubMed ID: 26706015
[TBL] [Abstract][Full Text] [Related]
17. Managing tuberous sclerosis in the Asia-Pacific region: refining practice and the role of targeted therapy.
Lawson JA; Chan CF; Chi CS; Fan PC; Kim HD; Kim KJ; Likasitwatanakul S; Ortiz M; Riney K; Tay SK; Tham CK
J Clin Neurosci; 2014 Jul; 21(7):1180-7. PubMed ID: 24518266
[TBL] [Abstract][Full Text] [Related]
18. Tuberous sclerosis-associated neuropsychiatric disorders: a paediatric cohort study.
Toldo I; Brasson V; Miscioscia M; Pelizza MF; Manara R; Sartori S; Mantegazza G; Vecchi M; Nosadini M; Gatta M
Dev Med Child Neurol; 2019 Feb; 61(2):168-173. PubMed ID: 30298907
[TBL] [Abstract][Full Text] [Related]
19. Tuberous sclerosis complex: advances in diagnosis, genetics, and management.
Schwartz RA; Fernández G; Kotulska K; Jóźwiak S
J Am Acad Dermatol; 2007 Aug; 57(2):189-202. PubMed ID: 17637444
[TBL] [Abstract][Full Text] [Related]
20. A Review of Investigations for Patients With Tuberous Sclerosis Complex Who Were Referred to the Tuberous Sclerosis Clinic at The Hospital for Sick Children: Identifying Gaps in Surveillance.
Alsowat D; Zak M; McCoy B; Kabir N; Al-Mehmadi S; Chan V; Whitney R
Pediatr Neurol; 2020 Jan; 102():44-48. PubMed ID: 31362847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
